Company Management

Michael Pehl

President and CEO
  • More than 20 years experience in Hematology and Oncology
  • Most recently President, Hematology & Oncology at Celgene
  • Launched multiple blockbuster drugs in oncology including Revlimid, Pomalyst, and Abraxane
  • Previously served at Amgen

Brendan P. Delaney

Chief Commercial Officer
  • More than 20 years of commercial oncology experience on block-buster brands
  • Most recently VP, U.S. Hematology/Oncology Commercial at Celgene
  • Previously served at Novartis and Genentech

Usama Malik

Chief Business Officer and Interim CFO
  • Responsible for business development, corporate and portfolio strategy, and corporate transformation
  • Global VP of Corporate Strategy, Innovation, and Digital Ventures at Pfizer Inc.
  • Previously served as senior executive & executive advisor at Novartis, BMS, Lily, Schering, Intarcia, Zoetis, Danaher, Quest Diagnostics, Aetna among others

Dr. Morris Rosenberg

Chief Technology Officer
  • Over 28 years of biologics drug development experience
  • Most recently, EVP of Development responsible for manufacturing, process development and supply chain management at Seattle Genetics

Dr. Robert Iannone

Head of Research & Development and Chief Medical Officer
  • More than 13 years of clinical drug development experience
  • Most recently, SVP and Head of Immuno-Oncology at AstraZeneca/MedImmune where he oversaw the development of Imfinzi
  • Previously was a leader in the development of Keytruda® at Merck Research Laboratories